BC Innovations | Oct 19, 2017

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
BC Innovations | Aug 18, 2016
Emerging Company Profile

Negative thinking for brain cancer

Sapience Therapeutics Inc. is developing a dominant-negative form of the transcription factor ATF5 to target refractory glioblastoma without touching the surrounding tissue, taking advantage of the fact the brain stops expressing the protein in early...
BC Extra | Jul 13, 2016
Financial News

Cancer newco Sapience raises $22.5M

Sapience Therapeutics Inc. (Scarsdale, N.Y.) raised $22.5 million in an untranched series A round led by Eshelman Ventures. Celgene Corp. (NASDAQ:CELG), TaiAn Technologies and Healthlink Capital also participated. Sapience's lead program, ST-36 , is a preclinical...
BC Innovations | Jun 3, 2010
Distillery Therapeutics

Indication: Cancer

Cancer Brain cancer Activating transcription factor 5 (ATF5); cAMP responsive element binding protein 3-like 2 (CREB3L2) Studies in vitro and in mice suggest that inhibiting CREB3L2 could help treat glioblastoma. CREB3L2 is a regulator of...
Items per page:
1 - 4 of 4